Peter S Mezes

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 585(Granted Patents)

Location History:

Midland, MI (US) (1995 - 2001)
Oldlyme, CT (US) (1999 - 2017)

Company Filing History:

13 out of 7,680

The Dow Chemical Company

patents

2 out of 45

Celldex Therapeutics Limited

National Institutes of Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2017

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9580503 - Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof (2017-02-28),

2. 8846873 - Antibodies directed to GPNMB and uses thereof (2014-09-30),

3. 8067544 - Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof (2011-11-29),

4. 7179899 - Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72 (2007-02-20),

5. 7141549 - Proteins and nucleic acids encoding same (2006-11-28),

6. 6641999 - Probing method for identifying antibodies specific for selected antigens (2003-11-04),

7. 6495137 - Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains (2002-12-17),

8. 6329507 - Dimer and multimer forms of single chain polypeptides (2001-12-11),

9. 6207815 - Family of high affinity, modified antibodies for cancer treatment (2001-03-27),

10. 6071515 - Dimer and multimer forms of single chain polypeptides (2000-06-06),

11. 6051225 - Family of high affinity, modified antibodies for cancer treatment (2000-04-18),

12. 6030792 - Assays for measurement of protein fragments in biological media (2000-02-29),

13. 5993813 - Family of high affinity, modified antibodies for cancer treatment (1999-11-30),

14. 5976845 - Composite antibodies of human subgroup IV light chain capable of binding (1999-11-02),

15. 5976531 - Composite antibodies of human subgroup IV light chain capable of binding (1999-11-02),

Title: Peter S. Mezes: Innovator in Monoclonal Antibody Development

Introduction

Peter S. Mezes is a prominent inventor based in Midland, MI, known for his groundbreaking work in the field of antibody research. With a remarkable portfolio of 19 patents, Mezes has made significant contributions to the development of fully human monoclonal antibodies aimed at providing innovative solutions in the medical and therapeutic domains.

Latest Patents

Among his noteworthy inventions, two recent patents stand out. The first patent focuses on antibodies against the T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen. This invention encompasses fully human monoclonal antibodies specifically directed towards TIM-1, along with isolated polynucleotide sequences that encode heavy and light chain immunoglobulin molecules. The provision of hybridomas and cell lines expressing such immunoglobulin molecules further enhances the applicability of this invention.

The second patent pertains to antibodies directed to GPNMB. It presents fully human monoclonal antibodies that bind specifically to GPNMB and outlines various applications for these antibodies. This patent also introduces immunoconjugates comprising anti-GPNMB antibodies and details the methods for using such bispecific antibodies, including an anti-CD3 component.

Career Highlights

Throughout his career, Peter S. Mezes has worked for renowned companies such as The Dow Chemical Company and Celldex Therapeutics Limited. His experience in these organizations has provided him with the necessary expertise to innovate and lead in the field of antibody technology.

Collaborations

Mezes has collaborated with distinguished professionals, including Brian B. Gourlie and Ruth A. Richard. These collaborations highlight the importance of teamwork and shared knowledge in the pursuit of innovative solutions in science and technology.

Conclusion

Peter S. Mezes exemplifies innovation in the field of monoclonal antibody development. With his extensive patent portfolio and collaboration with leading professionals in the field, he continues to pave the way for advancements that have the potential to significantly impact healthcare and therapeutic practices. His contributions will undoubtedly leave a lasting legacy in the world of antibody research.

This text is generated by artificial intelligence and may not be accurate.